AMAG Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
AMAG AMAG Pharmaceuticals Inc
HCI Hci Group Inc
PSF Cohen & Steers Select Preferred and Income Fund
PJT PJT Partners Inc
ALK Alaska Air Group Inc
RS Reliance Steel & Aluminum Co
HFWA Heritage Financial Corp
MET MetLife Inc
KALU Kaiser Aluminum Corp
STBA S&T Bancorp Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Closing Price
$13.67
Day's Change
0.01 (0.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.67
Day's Low
13.61
Volume
(Light)
Volume:
723,563

10-day average volume:
1,312,130
723,563

Peloton's stock soars toward another record as J.P. Morgan's Anmuth raises target to a Street high

8:10 am ET September 2, 2020 (MarketWatch)
Print

Shares of Peloton Interactive Inc. (PTON) ran up 7.9% toward record territory in premarket trading Wednesday, extending the 25.9% rally over the past six sessions, after J.P. Morgan analyst Doug Anmuth boosted his price target to the highest among Wall Street analysts, citing optimism ahead of next week's earnings report. Peloton is scheduled to report fiscal fourth-quarter results on Sept. 10. Anmuth reiterated the overweight rating he's had on the at-home fitness company since starting coverage in October, saying the stock is on J.P. Morgan's U.S. Analyst Focus List. He raised his price target to $105 from $58. Of the 26 analysts surveyed by FactSet, Anmuth's target is now the highest, and well above the average target of $67.38. Anmuth said Peloton's biggest challenge is keeping up with elevated demand amid the COVID-19 pandemic, has order-to-delivery times has averaged 6 to 7 weeks. "While the delay is not optimal, we believe it bodes well for ongoing demand and sustained top-line strength and could also cap marketing spend longer than we previously expected," Anmuth wrote in a note to clients. The company went public in September 2019 at an IPO price of $29. The stock has nearly tripled (up 195%) year to date, while the S&P 500 has gained 9.2%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 02, 2020 08:10 ET (12:10 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.